Amphastar Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 05/30/2023
Amphastar Pharmaceuticals Stock Forecast and Price Target
Amphastar Pharmaceuticals has an average price target of $44.00 recently offered by notable experts for 2023, which would represent a potential downside of approximately -0.79% from the last closing price in May, 2023 if reached. This potential increase is based on a high estimate of $45.00 and a low estimate of $37.00. If you are not interested in AMPH stock, you may be interested in its competitors.
-0.79% Downside
Amphastar Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Price for Amphastar Pharmaceuticals has grown by 280.56%, going from $15.30 to $58.23. In the next year, 0 analysts estimate that Amphastar Pharmaceuticals's Fair Value will decrease by 50.10%, reaching $29.05. According to professional forecasts, in 2030, Amphastar Pharmaceuticals's Fair Value will decrease by 34.44%, reaching $38.17.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
14
|
$427.51 | Buy/Sell | $333.19 | -6.43% |
| NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
10
|
kr967.50 | Buy/Sell | kr937.82 | 0.78% |
| SUNPHARMA Stock Forecast | Sun Pharmaceutical Industries | Outperform |
18
|
Rp1.01k | Buy/Sell | Rp845.39 | 2.61% |
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Hold |
12
|
$7.21 | Buy/Sell | $12.04 | 38.70% |
| HALO Stock Forecast | Halozyme Therapeutics | Outperform |
11
|
$32.86 | Buy/Sell | $56.22 | 85.64% |
Amphastar Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Revenue for Amphastar Pharmaceuticals has grown by 35.80%, going from $322.36M to $437.77M. In the next year, 0 analysts estimate that Amphastar Pharmaceuticals's Revenue will decrease by 16.01%, reaching $367.70M. According to professional forecasts, in 2030, Amphastar Pharmaceuticals's Revenue will decrease by 14.23%, reaching $375.49M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| HIK Stock Forecast | Hikma Pharmaceuticals PLC | Outperform |
18
|
£1.80k | Buy/Sell | £29.33 | -98.47% |
| PBH Stock Forecast | Prestige Consumer Healthcare | Buy |
16
|
$57.96 | Buy/Sell | $63.50 | 17.32% |
| BHC Stock Forecast | Bausch Health Companies | Hold |
15
|
$8.18 | Buy/Sell | $34.09 | -8.31% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$33.27 | Buy/Sell | $35.50 | 2.19% |
| EBS Stock Forecast | Emergent BioSolutions | Outperform |
16
|
$8.22 | Buy/Sell | $44.50 | 356.20% |
| ZEAL Stock Forecast | Zealand Pharma A/S | Outperform |
8
|
kr117.00 | Buy/Sell | kr241.83 | 70.94% |
Amphastar Pharmaceuticals Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Amphastar Pharmaceuticals's Free Cash Flow has grown, increasing from $200.00k to $70.53M – an increase of 35165.00%. 0 analysts predict Amphastar Pharmaceuticals's Free Cash Flow will decrease by 77.59% in the next year, reaching $15.81M. By 2030, professionals predict that Amphastar Pharmaceuticals's Free Cash Flow will decrease by 16.61%, to $58.81M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ANIP Stock Forecast | ANI Pharmaceuticals | Outperform |
13
|
$46.15 | Buy/Sell | $61.67 | -2.49% |
| EGRX Stock Forecast | Eagle Pharmaceuticals | Outperform |
14
|
$20.43 | Buy/Sell | $50.50 | 137.40% |
| AMRX Stock Forecast | Amneal Pharmaceuticals | Outperform |
16
|
$2.39 | Buy/Sell | $0.00 | 192.89% |
Amphastar Pharmaceuticals Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Amphastar Pharmaceuticals's Net Income has increased by 26.93%, going from $48.94M to $62.12M. In the next year, analysts are expecting an increase in Net Income, predicting it will reach $724.78M – an increase of 1066.74%. The Amphastar Pharmaceuticals forecast is for Net Income to reach $56.43B or grow by 90744.10%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| XERS Stock Forecast | Xeris Pharmaceuticals | Buy |
6
|
$2.64 | Buy/Sell | $0.00 | 127.27% |
| ENDP Stock Forecast | Endo International | Underperform |
14
|
$0.41 | Buy/Sell | $0.00 | 143.90% |
| ASRT Stock Forecast | Assertio Holdings | Outperform |
8
|
$5.51 | Buy/Sell | $5.83 | 8.89% |
Amphastar Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
Amphastar Pharmaceuticals's EBITDA has increased by 426.67% In the last two years, going from $18.07M to $95.17M. For the following year, the 0 analysts predict that Amphastar Pharmaceuticals's EBITDA will drop by 58.31%, reaching $39.67M. In 2030, the professionals' prediction is that AMPH's EBITDA will decrease by 35.84%, reaching $61.06M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| OPNT Stock Forecast | Opiant Pharmaceuticals | Buy |
10
|
$20.89 | Buy/Sell | $43.00 | 93.87% |
| LCI Stock Forecast | Lannett Company | Hold |
10
|
$0.62 | Buy/Sell | $2.25 | 262.90% |
| ACOR Stock Forecast | Acorda Therapeutics | - |
5
|
$0.45 | Buy/Sell | $5.00 | 11.11% |
Amphastar Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Amphastar Pharmaceuticals's EBIT has grown, increasing from $-40.00k to $71.69M – a growth of 179325.00%. In the following year, the 0 analysts surveyed believe that Amphastar Pharmaceuticals's EBIT will decrease by 87.78%, reaching $8.76M. Over the next nine years, experts anticipate that Amphastar Pharmaceuticals's EBIT will grow at a rate of 83.01%.
Amphastar Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, EPS for Amphastar Pharmaceuticals has grown by 280.56%, going from $0.36 to $1.37. In the next year, 0 analysts estimate that Amphastar Pharmaceuticals's EPS will decrease by 50.10%, reaching $0.68. According to professional forecasts, in 2030, Amphastar Pharmaceuticals's EPS will decrease by 34.44%, reaching $0.90.
Site Navigation
.jpg)